Displaying drugs 10626 - 10650 of 12610 in total
Ripertamab
Ripertamab is under investigation in clinical trial NCT02772822 (A Study Comparing the Efficiency and Safety of S-chop(cyclophosphamide, Hydroxydaunomycin, Oncovin, and Prednisone) Versus R-CHOP in Untreated Cd20(cluster of Differentiation Antigen 20)-positive DLBCL Patients).
Investigational
Matched Description: … Ripertamab is under investigation in clinical trial NCT02772822 (A Study Comparing the Efficiency and Safety of ... cyclophosphamide, Hydroxydaunomycin, Oncovin, and Prednisone) Versus R-CHOP in Untreated Cd20(cluster of …
Velsecorat
Velsecorat is under investigation in clinical trial NCT02479412 (A Multiple Dosing (14 Days) Study to Assess Efficacy and Safety of Three Dose Levels of AZD7594, Given Once Daily by Inhalation, in Patients With Mild to Moderate Asthma).
Investigational
Matched Description: … Three Dose Levels of AZD7594, Given Once Daily by Inhalation, in Patients With Mild to Moderate Asthma ... investigation in clinical trial NCT02479412 (A Multiple Dosing (14 Days) Study to Assess Efficacy and Safety of …
IMA901
IMA901 is a vaccine consists of tumor-associated peptides (TUMAPs).
Investigational
Matched Description: … IMA901 is a vaccine consists of tumor-associated peptides (TUMAPs). …
Napabucasin
Napabucasin has been investigated for the treatment of Colorectal Carcinoma.
Investigational
Matched Description: … Napabucasin has been investigated for the treatment of Colorectal Carcinoma. …
Cerlapirdine
Cerlapirdine has been investigated for the treatment of Alzheimer Disease.
Investigational
Matched Description: … Cerlapirdine has been investigated for the treatment of Alzheimer Disease. …
Puerarin
Puerarin has been investigated for the treatment of Alcohol Abuse.
Investigational
Matched Description: … Puerarin has been investigated for the treatment of Alcohol Abuse. …
AC-430
AC430 has been investigated for the treatment of Rheumatoid Arthritis.
Investigational
Matched Description: … AC430 has been investigated for the treatment of Rheumatoid Arthritis. …
Vamifeport
Vamifeport is being investigated for the treatment of beta-thalassemia.
Investigational
Matched Description: … Vamifeport is being investigated for the treatment of beta-thalassemia. …
TZ-101
TZ-101 composes of GDP-L-fucose and fucosyltransferase VI
Investigational
Matched Description: … TZ-101 composes of [GDP-L-fucose] and fucosyltransferase VI …
NM-702
Nissan Chemical and Taisho have been jointly developing NM-702, a drug for the treatment of arteriosclerosis obliterans.
M-702 is an orally active inhibitor of phosphodiesterase and thromboxane synthetase. In Japan, Phase 2 studies are being conducted for intermittent claudication caused by arteriosclerosis obliterans, intermittent claudication caused by spinal canal stenosis,...
Investigational
Matched Description: … sclerosis of peripheral arteries. ... Intermittent claudication is a major symptom of arteriosclerosis obliterans. ... M-702 is an orally active inhibitor of phosphodiesterase and thromboxane synthetase. …
4-Methyl-2,5-dimethoxyamphetamine
A psychedelic phenyl isopropylamine derivative, commonly called DOM, whose mood-altering effects and mechanism of action may be similar to those of LSD.
Experimental
Illicit
Matched Description: … action may be similar to those of LSD. ... psychedelic phenyl isopropylamine derivative, commonly called DOM, whose mood-altering effects and mechanism of …
Endostar
Endostar is under investigation for the treatment of Nasopharyngeal Carcinoma. Endostar has been investigated for the treatment of Non-small Cell Lung Cancer.
Investigational
Matched Description: … Endostar is under investigation for the treatment of Nasopharyngeal Carcinoma. ... Endostar has been investigated for the treatment of Non-small Cell Lung Cancer. …
Opicinumab
Opicinumab is under investigation in clinical trial NCT02641041 (Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of BIIB033 in Healthy Japanese Participants).
Investigational
Matched Description: … Single and Multiple Doses of BIIB033 in Healthy Japanese Participants). ... Opicinumab is under investigation in clinical trial NCT02641041 (Safety, Tolerability, and Pharmacokinetics of …
ARC-19499
ARC-19499 is under investigation in clinical trial NCT01191372 (First-in-Human and Proof-of-Mechanism Study of ARC19499 Administered to Hemophilia Patients).
Investigational
Matched Description: … Study of ARC19499 Administered to Hemophilia Patients). ... ARC-19499 is under investigation in clinical trial NCT01191372 (First-in-Human and Proof-of-Mechanism …
Rimtuzalcap
Rimtuzalcap is a novel modulator of small-conductance calcium-activated potassium channels that is under investigation for the treatment of essential tremor.
Investigational
Matched Description: … investigation for the treatment of essential tremor. ... Rimtuzalcap is a novel modulator of small-conductance calcium-activated potassium channels that is under …
ACA 125
An IgG1 murine monoclonal anti-idiotype antibody (Ab2), ACA-125, was developed to bind to anti-CA 125 antibodies. ACA-125 mimics the tumor-associated antigen CA-125, which can be detected in about 80% of ovarian carcinomas.
This new concept of oncological immunotherapy consists of an attempt to trigger the immune system of the host...
Investigational
Matched Description: … This new concept of oncological immunotherapy consists of an attempt to trigger the immune system of ... Antiidiotypic antibodies bearing the internal image of an antigen expressed on the surface of the tumor ... ACA-125 mimics the tumor-associated antigen CA-125, which can be detected in about 80% of ovarian carcinomas …
REP8839
REP8839 is a novel methionyl-tRNA synthetase (MetS) inhibitor being developed by Replidyne (GlaxoSmithKline licensed REP8839 to Replidyne in June of 2003).
Investigational
Matched Description: … MetS) inhibitor being developed by Replidyne (GlaxoSmithKline licensed REP8839 to Replidyne in June of …
VXA-CoV2-1
VXA-CoV2-1 is a non-replicating adenoviral vector-based oral tableted vaccine candidate that expresses a SARS-CoV-2 antigen and dsRNA adjuvant . This oral vaccine aims to induce immunogenicity through induction of potent serum neutralizing antibodies to the SARS-CoV-2 spike protein, induction of mucosal immune responses, and induction of T-cell responses to both...
Investigational
Matched Description: … to the SARS-CoV-2 spike protein, induction of mucosal immune responses, and induction of T-cell responses ... to both vaccine antigens of the SARS-CoV-2 nucleocapsid and spike proteins[L30498]. ... This oral vaccine aims to induce immunogenicity through induction of potent serum neutralizing antibodies …
Artefenomel
Artefenomel has been investigated for the treatment of Malaria.
Investigational
Matched Description: … Artefenomel has been investigated for the treatment of Malaria. …
Pyronaridine
Pyronaridine has been investigated for the treatment of Malaria.
Investigational
Matched Description: … Pyronaridine has been investigated for the treatment of Malaria. …
Enecadin
Enecadin has been investigated for the treatment of Stroke.
Investigational
Matched Description: … Enecadin has been investigated for the treatment of Stroke. …
SB-218078
SB-218078 is a specific inhibitor of CHK1.
Investigational
Matched Description: … SB-218078 is a specific inhibitor of CHK1.[A253117] …
ISIS 113715
ISIS 113715 is our second-generation antisense inhibitor of protein tyrosine phosphatase 1b, or PTP‑1b, for the treatment of type 2 diabetes. In early trials, ISIS 113715 induced statistically significant improvements in multiple measures of glucose control along with statistically significant
reductions in LDL-cholesterol.
Investigational
Matched Description: … , for the treatment of type 2 diabetes. ... ISIS 113715 is our second-generation antisense inhibitor of protein tyrosine phosphatase 1b, or PTP‑1b ... In early trials, ISIS 113715 induced statistically significant improvements in multiple measures of glucose …
RUS 3108
RUS 3108 is being developed for the treatment of atherosclerosis, the major cause of cardiovascular disorders such as heart attacks and stroke by Dr. Reddy’s Laboratories.
The drug’s Phase I clinical trials have been initiated in Europe to assess safety of the drug compound in healthy volunteers.
Investigational
Matched Description: … RUS 3108 is being developed for the treatment of atherosclerosis, the major cause of cardiovascular disorders ... The drug’s Phase I clinical trials have been initiated in Europe to assess safety of the drug compound …
VY-HTT01
VY-HTT01 is a gene therapy designed to reduce the expression of huntingtin, thereby altering disease progression. VY-HTT01 is comprised of an adeno-associated virus capsid (AAV1) and a proprietary transgene that harnesses the canonical RNA interference pathway to selectively knock down levels of HTT mRNA.
Investigational
Matched Description: … the canonical RNA interference pathway to selectively knock down levels of HTT mRNA. ... VY-HTT01 is a gene therapy designed to reduce the expression of huntingtin, thereby altering disease ... VY-HTT01 is comprised of an adeno-associated virus capsid (AAV1) and a proprietary transgene that harnesses …
Displaying drugs 10626 - 10650 of 12610 in total